SK Bioscience Announces IR for 2026 Q1 Results
-
SK Bioscience will hold an IR meeting for major domestic institutional investors on May 7-8, 2026, to discuss 2026 Q1 earnings and business status.
-
The meeting will be held in person, sponsored by DB Securities. Related materials will be posted on the company's website.
KOSPI Filing Information
-
Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
-
Company: SK Bioscience (302440)
-
Submission: SK Bioscience Co.,Ltd
-
Receipt: 05-06-2026
-
Under KRX KOSPI Market Division